外科视角下《WHO成人肥胖GLP-1药物应用与适应证指南》解读:机遇、挑战与中国临床路径思考OA
Interpretation of the World Health Organization guideline on the use and indications of GLP-1 therapies for the treatment of obesity in adults from a surgical perspective:opportunities,challenges,and implications for clinical pathways in China
世界卫生组织近期发布《成人肥胖GLP-1药物应用与适应证指南》,标志着以GLP-1受体激动剂为代表的药物治疗在肥胖管理中的地位进一步确立.本文从外科视角系统解读该指南核心内容,重点分析GLP-1治疗对肥胖症治疗格局的重塑作用及其对减重与代谢外科带来的机遇与挑战,并结合我国医疗实践,探讨药物与手术协同应用的临床路径.旨在为优化肥胖症综合管理策略提供参考.
The recent release of the World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults further establishes the role of GLP-1 receptor agonists in obesity management.From a surgical perspective,this article systematically interprets the key recommendations of the guideline,with a focus on the impact of GLP-1-based therapies on the current treatment paradigm and their implications for bariatric and metabolic surgery.In addition,the potential clinical pathways for integrating pharmacological and surgical approaches in China are discussed,aiming to provide insights for optimizing comprehensive obesity management.
刘晨鸣;张鹏
首都医科大学附属北京友谊医院 普通外科中心减重与代谢外科||国家消化系统疾病临床医学研究中心||消化健康全国重点实验室,北京 100050首都医科大学附属北京友谊医院 普通外科中心减重与代谢外科||国家消化系统疾病临床医学研究中心||消化健康全国重点实验室,北京 100050
医药卫生
肥胖症胰高血糖素样肽-1受体激动剂减肥手术解读
ObesityGlucagon-Like Peptide-1 Receptor AgonistsBariatric SurgeryInterpretation
《中国普通外科杂志》 2026 (2)
223-229,7
国家重点研发计划资助项目(2022YFC2505204)四大慢病重大专项基金资助项目(2025ZD0550503).
评论